FDA Releases New Guidance on Postapproval Pregnancy Safety Studies for Drugs and Biologics

The FDA has released new guidance on postapproval pregnancy safety studies for drugs and biologics, highlighting pregnancy registries, real-world evidence, and postmarketing surveillance expectations for manufacturers.